Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria

https://doi.org/10.17749/2070-4909.2019.12.2.72-84

Full Text:

Abstract

Aim: to assess the economic outcomes of using ceftazidime + avibactam (compared with the recommended treatments) in adult patients with sepsis caused by carbapenem-resistant enterobacteria.

Methods. The economic assessment was made using the cost-effectiveness analysis and budget impact analysis. The cost-effectiveness and budget impact analyses were performed using the Microsoft Excel software.

Results. The treatment efficacy analysis showed that patients treated with the fixed-dose combination ceftazidime + avibactam had fewer days spent in the ICU and higher clinical cure rates than patients receiving the reference drug combinations (8 vs 18 days and 75% vs 34.8%, respectively, p=0.031). The cost of treatment with ceftazidime + avibactam amounted to 228.3 thousand rubles, which was lower than the cost of using the alternative treatment regimens by 34.5-229.5 thousand rubles or 13.12-50.14%. According to the cost-effectiveness analysis, the use of ceftazidime + avibactam is pharmacoeconomically effective as it reduces the cost of patient clinical cure case by 61-72% (depending on the treatment regimen used); in addition, the ceftazidime + avibactam allows for managing the hospitalized patient at a cost lower by 76270 thousand rubles or 16-40% than the compared treatment. The median economic benefit from using the fixed dose combination ceftazidime + avibactam is 154 thousand rubles (28% savings compared with the current practice). The budget impact analysis showed that the reduction in the health budget burden would reach 29% or 34.3 million rubles in year. The sensitivity analysis confirmed the above results.

Conclusion. Based on the obtained results, we conclude that the ceftazidime + avibactam combination in patients with sepsis caused by carbapenem-resistant bacteria is economically preferable as compared with the current antibiotic therapy regimens.

About the Authors

S. V. Nedogoda
Volgograd State Medical University
Russian Federation

Sergei V. Nedogoda - MD, PhD, Professor, Head of the Department of Internal Disease and Endocrinology, Faculty of Advanced Medical Studies.

1 pl. Pavshikh Bortsov, Volgograd 400131



A. S. Salasyuk
Volgograd State Medical University
Russian Federation

Alla S. Salasyuk - MD, PhD, Assistant at the Department of Internal Disease and Endocrinology, Faculty of Advanced Medical Studies.

1 pl. Pavshikh Bortsov, Volgograd 400131



I. N. Barykina
Volgograd State Medical University
Russian Federation

Irina N. Barykina - MD, PhD, Associate Professor at the Department of Internal Disease and Endocrinology, Faculty of Advanced Medical Studies.

1 pl. Pavshikh Bortsov, Volgograd 400131



V. O. Smirnova
Volgograd State Medical University
Russian Federation

Viktoriya O. Smirnova - MD, PhD Student at the Department of Internal Disease and Endocrinology, Faculty of Advanced Medical Studies.

1 pl. Pavshikh Bortsov, Volgograd 400131



References

1. Algorithm of antimicrobial therapy for sepsis. Russian Association of Surgical Infection Specialists (RAAS). Kaluga 2004; 19 s. (in Russ.)

2. Clinical recommendations for the diagnosis and treatment of severe sepsis and septic shock in treatment-and-prophylactic organizations of St. Petersburg, 2016. (In Russ).

3. The SCAT program (Antimicrobial Therapy Control Strategy) for inpatient care. Russian clinical guidelines. 2017. (In Russ).

4. Kozlov R. S., Stetsyuk O. U., Andreeva I. V. Ceftazidim-avi-bakam: new “rules of the game” against multidrug-resistant gram-negative bacteria. Klinicheskaya mikrobiologiya i antimikrobnaya khimi-oterapiya. (In Russ). 2018; 20 (1): 24-34.

5. Zhanel G.G., et al. Ceftazidime-avibactam: a novel cephalospo-rin/p-lactamase inhibitor combination. Drugs. 2013; 73 (2): 159-177. DOI: https://dx.doi.org/10.1007/s40265-013-0013-7

6. Lagace-Wiens P., Walkty A., Karlowsky J.A. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core evidence. 2014; 9 (13): 13-25. DOI: https://dx.doi.org/10.2147/CE.S40698

7. Zilberberg M.D., Shorr A.F., Micek S.T. et al Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care. 2014; 18 (6): 596. DOI: 10.1186/s13054-014-0596-8.

8. Caston J.J., et al. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbap-enemase-producing Enterobacteriaceae in hematologic patients. International Journal of Infectious Diseases. 2017; 59: 118-123. DOI:https://doi.org/10.1016/j.ijid.2017.03.021

9. State report “On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2017”. [Electronic resource] URL: http://rospotrebnadzor.ru/upload/iblock/d9d/gd_2017_seb.pdf. Accessed: 21.04.2019

10. Yakovlev S.V., Suvorova M.P., Beloborodov V.B., Basin E.E., Eliseeva E.V., Kovelenov S.V., Portnyagina U.S., Rog A.A., Rudnov V.A., Barkanova O.N. Prevalence and clinical significance of nosocomial infections in Russian medical institutions: ERGINI study. Antibiotiki i khimioterapiya. (In Russ). 2016; 61 (5-6): 32-42.

11. Kuz’menkov A.Ju., Trushin I.V., Avramenko A.A., Jejdel’shtejn M.V., Dehnich A.V., Kozlov R.S. AMRmap: an online antimicrobial resistance monitoring platform. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya (In Russ). 2017; 19 (2): 84-90.


For citation:


Nedogoda S.V., Salasyuk A.S., Barykina I.N., Smirnova V.O. Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2019;12(2):72-84. (In Russ.) https://doi.org/10.17749/2070-4909.2019.12.2.72-84

Views: 206


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)